Compare LIND & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LIND | IOVA |
|---|---|---|
| Founded | 1979 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 2011 | 2008 |
| Metric | LIND | IOVA |
|---|---|---|
| Price | $25.80 | $8.58 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $22.25 | $9.00 |
| AVG Volume (30 Days) | 773.1K | ★ 13.9M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 5.97 | ★ 14.84 |
| EPS | ★ 0.07 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.98 | $47.74 |
| Revenue Next Year | $6.98 | $40.31 |
| P/E Ratio | $362.21 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.37 | $1.76 |
| 52 Week High | $35.00 | $9.36 |
| Indicator | LIND | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 30.65 | 58.06 |
| Support Level | $24.79 | $7.66 |
| Resistance Level | $30.00 | $9.36 |
| Average True Range (ATR) | 1.26 | 0.45 |
| MACD | -0.64 | -0.10 |
| Stochastic Oscillator | 10.99 | 27.37 |
Lindblad Expeditions Holdings Inc provides expedition cruising and adventure travel services. The company operates in two segments: Lindblad and Land Experiences, of which Lindblad generates the vast majority of its revenue. It offers itineraries that feature up-close encounters with wildlife, nature, history, and culture, as well as promote guest empowerment and interactivity. It operates expeditions on intimately-scaled ships and interaction between guests, crew, and the teams of scientists, naturalists, researchers, and photographers that participate in the expeditions. Lindblad operates a fleet of twelve owned expedition ships and five seasonal charter vessels under the Lindblad brand.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.